PYMNTS.com January 22, 2024
Karen Webster

Trying to get rid of the middleman seems to be a universal business pastime.

Companies spend billions trying to “go direct” to gather first-party data, exert more control over the customer experience and cut out the middleman fees. Investors pour tens of billions into startups with tech to make it easier for brands to open their virtual storefronts, establish a social presence, find customers and make sales without using an intermediary. And regulators and lawmakers spend lots of hours working to break up the middlemen whose aim was to make it easier for buyers and sellers to find each other and do business at scale on a single platform.

Lots of middlemen are valuable, unavoidable — we’d miss them if...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Digital Health, Patient / Consumer, Pharma, Pharma / Biotech, Provider, Technology, Telehealth
5 Key AI Players Leading the Drug Discovery Push
Physicians hop on the GLP-1 train
STAT+: Two biotechs say they’re using AI to conjure drugs from scratch. Their documents suggest otherwise
Navigating Challenges in Drug-Device Combinations under EU MDR Article 117
Pharma Pulse 2/10/25: How 2025 Will Reshape Patient Support, ‘Food is Medicine’ & more

Share This Article